AKESO INC. O.N.(4RY)

Description: Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

---

Keywords: Biotechnology Cancer Biopharmaceutical Immunology Solid Tumors Immune System Cancer Immunotherapy Monoclonal Antibody Non Small Cell Lung Cancer Lung Cancer Acute Myeloid Leukemia Pancreatic Cancer Ulcerative Colitis Small Cell Lung Cancer Hepatocellular Carcinoma Head And Neck Cancer Myelodysplastic Syndrome Cervical Cancer Nsclc Hypercholesterolemia Triple Negative Breast Cancer Hodgkin Gastric Cancer Thyroid Cancer Ankylosing Spondylitis Mesothelioma Cholangiocarcinoma Neuroendocrine Tumor Sclc Tigit Ak104 Atezolizumab Classic Hodgkin's Lymphoma Colorectal And Ovarian Cancer Deficient Solid Tumor Moderate To Severe Atopic Dermatitis Moderate To Severe Psoriasis Solid Tumors/Lymphoma Thymic Cancer

---

Home Page: www.akesobio.com

No. 6, Shennong Road
Zhongshan, 528437
China
Phone: 86 76 0898 73998

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)